Literature DB >> 21208277

Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles.

Li Qin Li1, Hui Lian Huang, Jin Liang Ping, Wei Xu, Jing Li, Li Cheng Dai.   

Abstract

The aim of this study was to investigate the midkine and endoglin expression in breast carcinomas with five different immunohistochemical profiles and their relevance to histopathologic and clinicopathologic features. We analyzed 161 archival tissues immunohistologically. The level of midkine expression in breast cancer significantly correlated with lymph node metastasis (p = 0.001) and TNM staging (p = 0.003). High microvessel density (MVD) was associated with higher midkine reactivity group (p = 0.036). Although the basal-like subtype had higher midkine expression level and MVD, no significant difference with the other breast cancer subtypes was found. In conclusion, midkine was a promising target for tumor prognosis in clinical diagnosis and treatment. This study found no significant differences in tumor angiogenesis in different molecular subtypes of breast cancer.
© 2010 The Authors. APMIS © 2010 APMIS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21208277     DOI: 10.1111/j.1600-0463.2010.02699.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  3 in total

1.  The clinical and prognostic significance of midkine in breast cancer patients.

Authors:  Fuguang Li; Peijun Tian; Jun Zhang; Changyuan Kou
Journal:  Tumour Biol       Date:  2015-07-10

2.  Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer.

Authors:  Hua Shao; Xiaohui Yu; Cuifang Wang; Qiang Wang; Haixia Guan
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

3.  Transcriptome analysis of the hormone-sensing cells in mammary epithelial reveals dynamic changes in early pregnancy.

Authors:  Duvini De Silva; Kamini Kunasegaran; Sujoy Ghosh; Alexandra M Pietersen
Journal:  BMC Dev Biol       Date:  2015-01-27       Impact factor: 1.978

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.